Mechanistic Vs. Empirical Network Models of Drug Action

Declining success rates coupled with increased costs is leading to an inevitable breaking point in the drug development pipeline. Can we avoid it by incorporating the vast mechanistic understanding of drug action? A recent review highlights this dilemma and proposes “quantitative logic gate” modelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Birtwistle, M R, Mager, D E, Gallo, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026635/
https://www.ncbi.nlm.nih.gov/pubmed/24448020
http://dx.doi.org/10.1038/psp.2013.51
_version_ 1782316870498516992
author Birtwistle, M R
Mager, D E
Gallo, J M
author_facet Birtwistle, M R
Mager, D E
Gallo, J M
author_sort Birtwistle, M R
collection PubMed
description Declining success rates coupled with increased costs is leading to an inevitable breaking point in the drug development pipeline. Can we avoid it by incorporating the vast mechanistic understanding of drug action? A recent review highlights this dilemma and proposes “quantitative logic gate” modeling as a solution.(1) The goal of this commentary is to contrast this approach with mechanistic biochemical network models, which, although alluded to by Kiruoac and Onsum, requires a closer analysis.
format Online
Article
Text
id pubmed-4026635
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40266352014-05-20 Mechanistic Vs. Empirical Network Models of Drug Action Birtwistle, M R Mager, D E Gallo, J M CPT Pharmacometrics Syst Pharmacol Commentary Declining success rates coupled with increased costs is leading to an inevitable breaking point in the drug development pipeline. Can we avoid it by incorporating the vast mechanistic understanding of drug action? A recent review highlights this dilemma and proposes “quantitative logic gate” modeling as a solution.(1) The goal of this commentary is to contrast this approach with mechanistic biochemical network models, which, although alluded to by Kiruoac and Onsum, requires a closer analysis. Nature Publishing Group 2013-09 2013-09-06 /pmc/articles/PMC4026635/ /pubmed/24448020 http://dx.doi.org/10.1038/psp.2013.51 Text en Copyright © 2013 American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ CPT: Pharmacometrics and Systems Pharmacology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Commentary
Birtwistle, M R
Mager, D E
Gallo, J M
Mechanistic Vs. Empirical Network Models of Drug Action
title Mechanistic Vs. Empirical Network Models of Drug Action
title_full Mechanistic Vs. Empirical Network Models of Drug Action
title_fullStr Mechanistic Vs. Empirical Network Models of Drug Action
title_full_unstemmed Mechanistic Vs. Empirical Network Models of Drug Action
title_short Mechanistic Vs. Empirical Network Models of Drug Action
title_sort mechanistic vs. empirical network models of drug action
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026635/
https://www.ncbi.nlm.nih.gov/pubmed/24448020
http://dx.doi.org/10.1038/psp.2013.51
work_keys_str_mv AT birtwistlemr mechanisticvsempiricalnetworkmodelsofdrugaction
AT magerde mechanisticvsempiricalnetworkmodelsofdrugaction
AT gallojm mechanisticvsempiricalnetworkmodelsofdrugaction

Ejemplares similares